PMID- 30834335
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 2397-9070 (Electronic)
IS  - 2397-9070 (Linking)
VI  - 3
IP  - 1
DP  - 2019 Feb
TI  - Specific adverse events predict survival rates in a Chinese population diagnosed 
      with hepatocellular carcinoma and treated with sorafenib.
PG  - 10-16
LID - 10.1002/jgh3.12096 [doi]
AB  - Hepatocellular carcinoma (HCC) is associated with a poor prognosis and a low 
      chemotherapeutic efficiency except for when sorafenib is administered. The aim of 
      this study was to evaluate the efficacy and adverse events (AEs) of sorafenib 
      therapy in a Chinese population diagnosed with HCC. METHOD: Data for the subjects 
      with HCC receiving sorafenib at Taichung Veterans General Hospital from June 2012 
      to October 2016 were evaluated. All enrolled cases belonged to the HCC Barcelona 
      Clinic Liver Cancer (BCLC) classification stage C. The AEs were defined as 
      appearances of hand-foot syndrome reaction (HFSR), hypertension (HTN), or 
      diarrhea. The exclusion criteria included a poor performance status, lack of 
      compliance to drugs, and loss of follow-up within the following day. RESULTS: Of 
      a total of 116 subjects enrolled, there were 43 (37.1%), 13 (11.2%), and 15 
      (12.9%) cases experiencing HFSR, HTN, and diarrhea, respectively. The cases with 
      AE had both a longer time to progression (TTP) (HFSR 5.16 vs. 3.33 months, 
      P = 0.003; HTN 6.62 vs. 3.68 months, P = 0.001; diarrhea 6.67 vs. 3.61 months, 
      P = 0.001) and overall survival (OS) (HFSR 8.12 vs. 4.75 months, P = 0.001; HTN 
      9.08 vs. 5.61 months, P = 0.008; diarrhea 8.20 vs. 5.67 months, P = 0.042) than 
      those without. More AEs were correlated with a longer TTP and OS. CONCLUSION: The 
      appearance of sorafenib AEs, including HFSR, HTN, and diarrhea, can predict a 
      positive therapy efficacy to HCC.
FAU - Lee, Shou-Wu
AU  - Lee SW
AUID- ORCID: 0000-0002-2412-2665
AD  - Division of Gastroenterology, Department of Internal Medicine Taichung Veterans 
      General Hospital Taichung Taiwan.
AD  - Department of Internal Medicine Chung Shan Medical University Taichung Taiwan.
FAU - Lee, Teng-Yu
AU  - Lee TY
AD  - Division of Gastroenterology, Department of Internal Medicine Taichung Veterans 
      General Hospital Taichung Taiwan.
AD  - Department of Internal Medicine Chung Shan Medical University Taichung Taiwan.
FAU - Yang, Sheng-Shun
AU  - Yang SS
AD  - Division of Gastroenterology, Department of Internal Medicine Taichung Veterans 
      General Hospital Taichung Taiwan.
AD  - Department of Internal Medicine Yang-Ming University Taipei Taiwan.
FAU - Peng, Yen-Chun
AU  - Peng YC
AD  - Division of Gastroenterology, Department of Internal Medicine Taichung Veterans 
      General Hospital Taichung Taiwan.
AD  - Department of Internal Medicine Yang-Ming University Taipei Taiwan.
FAU - Yeh, Hong-Zen
AU  - Yeh HZ
AD  - Division of Gastroenterology, Department of Internal Medicine Taichung Veterans 
      General Hospital Taichung Taiwan.
AD  - Department of Internal Medicine Yang-Ming University Taipei Taiwan.
FAU - Chang, Chi-Sen
AU  - Chang CS
AD  - Division of Gastroenterology, Department of Internal Medicine Taichung Veterans 
      General Hospital Taichung Taiwan.
AD  - Department of Internal Medicine Chung Shan Medical University Taichung Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20181015
PL  - Australia
TA  - JGH Open
JT  - JGH open : an open access journal of gastroenterology and hepatology
JID - 101730833
PMC - PMC6386742
OTO - NOTNLM
OT  - hand-foot skin reaction
OT  - hepatocellular carcinoma
OT  - sorafenib
EDAT- 2019/03/06 06:00
MHDA- 2019/03/06 06:01
PMCR- 2018/10/15
CRDT- 2019/03/06 06:00
PHST- 2018/07/19 00:00 [received]
PHST- 2018/08/28 00:00 [revised]
PHST- 2018/08/30 00:00 [accepted]
PHST- 2019/03/06 06:00 [entrez]
PHST- 2019/03/06 06:00 [pubmed]
PHST- 2019/03/06 06:01 [medline]
PHST- 2018/10/15 00:00 [pmc-release]
AID - JGH312096 [pii]
AID - 10.1002/jgh3.12096 [doi]
PST - epublish
SO  - JGH Open. 2018 Oct 15;3(1):10-16. doi: 10.1002/jgh3.12096. eCollection 2019 Feb.